The microbiome market comprises of sales of bioactive molecules and linked products which are utilized as immunotherapeutic agents in pharmaceuticals industry. The microbiome market is principally engaged in the improvement and sales of such bioactive products which are utilized as immunotherapy for a wide variability of conditions such as infectious syndromes, endocrine & metabolic disorders, inflammatory conditions, cancer, irritable bowel syndrome, neurological syndromes, hematological disorders and cardiovascular sickness as well.
According to the report analysis, ‘Microbiome
Global Market Report 2020-30: Covid 19 Impact and Recovery’ states that
during January 2020, Psomagen-Macrogen Consortium obtained uBiome for a deal
amount of USD 7.05 Million. The deal contains of patent portfolio of 246
patents (60 enumerated US patents and 186 applications), approximately 300,000
sample data and laboratory equipment. The Psomagen has become a foremost player
in the microbiome segment with this acquisition.
Additionally, the worldwide microbiome market is predicted to reduce from USD 0.34 billion during 2019 to USD 0.27 billion throughout 2020 at a compound annual growth rate (CAGR) of -20%. The deduction is mainly owing to the aim on Covid-19 outbreak and its treatment around the globe, resulting in patients of other sicknesses delaying their episodes of care. The market is then projected to recover and reach USD 0.58 billion during 2023 at a CAGR of 14%. North America was the chief region in the microbiome market during 2019. The microbiome market around Asia Pacific is reviewed to register the maximum CAGR during 2019-2023.
Although, the augmented number of
lifestyle syndromes such as diabetes, cancer, depression and several others in
the historical duration has positively affected the microbiome market.
Lifestyle transform the influences the micro flora inside at every stage of
life leading to lifestyle sicknesses and thus fluctuating the microbiome can
support in decreasing such lifestyle diseases. Around the globe from 1975 the
obesity population has approximately tripled and now 30% of the populace is
obese. During recent studies, Fecal Microbiome Transplantation has presented
the beneficial results in treating patients with obesity and also diabetes.
Thus, growing lifestyle transformations which lead to lifestyle diseases
support drive the growth of this market.
Nonetheless, there are several
major players in the microbiome market such as Enterome Bioscience, Vedanta
Biosciences Inc., Osel Inc., Synlogic Inc., Second Genome, Seres Therapeutics,
Synthetic Biologics Inc., uBiome, Inc., Metabiomics Corporate, Rebiotix Inc for
leading the highest market growth and dominating the handsome value of market
share around the globe.
Not only has this, the
technological advancements such as software programs enable easy analyzing of
the metagenomic datasets connected to the genes of the microbiota along with
the user-friendliness, effortlessness of access and with ability to deliver the
graphical representation for convenient and quick understanding of the analyzed
data. Specialized software programs prevail for analyzing the metagenomic data
are FastQC, Fastx-Toolkit, PRINSEQ, and several others. Thus, technological
improvements and innovative methods aid in growth of the human microbiome
market. Therefore, in the near years, it is predicted that the market of
microbiome will increase around the globe more effectively over the upcoming
years.
For More Information, Click on the Link Below:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing &
Communications
No comments:
Post a Comment